

Sun – Recall of Fyremadel® (ganirelix acetate) injection

- On April 18, 2023, <u>Sun announced</u> a consumer-level recall of one lot of <u>Fyremadel (ganirelix acetate)</u> injection because glass particulate was observed in one syringe.
 - Other Fyremadel injection products are available for patients to use.

Product Description	NDC	Lot number
Fyremadel (ganirelix acetate) injection, 250 mcg/0.5 mL	55566-1010-1	HAD1190A

- Fyremadel injection is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
- To date, Sun has not received any reports of adverse events with this lot number related to this
 recall.
- Contact Sun by phone at 1-800-406-7984 or by email at <u>drug.safetyUSA@sunpharma.com</u> for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.